I’m an obesity expert and can’t wait for the compounding craze to stop

A telemedicine obesity physician is urging the FDA to more forcefully police compounded GLP-1 sales, arguing that low cost and vitamin-B12 additions do not establish a legitimate medical need for compounding. The FDA earlier sent warning letters to 30 telehealth companies over advertising that blurred approved and compounded GLP-1s, while an advisory panel recently recommended allowing six unapproved peptides to be compounded in bulk. The commentary flags risks of inadequate clinical supervision, sterility failures, dosing errors and uncertain product contents, creating potential regulatory downside for online compounded-GLP-1 sellers.

Analysis

The investable issue is not a near-term demand inflection for branded incretins; it is the durability of the low-price substitute channel that has restrained realized pricing and diverted cash-pay patients. A formal FDA clarification narrowing “clinical need” and rejecting cosmetic formulation changes as a compounding rationale would improve Novo Nordisk (NVO) and Eli Lilly (LLY) mix, adherence visibility, and US net-price negotiating leverage over the next 6-18 months. The larger second-order beneficiary is likely branded distribution and specialty-pharmacy infrastructure, while telehealth platforms dependent on compounded offerings face customer-acquisition disruption, refund/liability costs, and materially higher churn.

The immediate catalyst path is regulatory rather than clinical: warning letters alone are weak, but enforcement actions against pharmacies, prescribers, or misleading direct-to-consumer marketing could force rapid product removals within days to weeks. That would create an initially favorable supply-demand imbalance for branded GLP-1s, although the upside is capped if payer coverage remains restrictive; displaced cash-pay consumers may simply exit treatment rather than convert. Watch NVO/LLY commentary on cash-pay conversion, prescription abandonment, and net price per patient rather than headline prescription volumes.

Consensus likely overstates the binary benefit to NVO and LLY. Restricting compounded supply may invite political scrutiny of branded list prices and accelerate pressure for lower-cost authorized cash-pay channels, potentially exchanging volume upside for lower realized price. The thesis is falsified if enforcement remains limited to advertising language, compounding pharmacies retain legal pathways through individualized formulations, or branded manufacturers report no improvement in cash-pay persistence despite tighter enforcement.

Key Decisions for Investors

• Maintain a 6-12 month long bias in LLY over NVO: Lilly has greater near-term US obesity capacity expansion and can capture displaced cash-pay demand more quickly. Prefer entry on regulatory-confirmed weakness rather than positioning ahead of nonbinding guidance; reassess if obesity net price deteriorates or Zepbound prescription growth fails to accelerate over two reporting periods.
• Use a relative-value pair, long LLY / short a basket of GLP-1-exposed telehealth or consumer-health platforms only after identifying disclosed compounded-GLP-1 revenue exposure. Do not initiate from this commentary alone: the key missing data are product-level revenue mix, pharmacy relationships, and contractual ability to pivot to branded fulfillment.
• Monitor FDA enforcement dockets and branded cash-pay program metrics over the next 1-3 months. A named enforcement action or mandatory product withdrawal is a catalyst to add to branded obesity exposure; absence of action after 90 days argues this remains reputational noise rather than an earnings event.
• Avoid treating a crackdown as an unqualified long catalyst for NVO/LLY. Hedge branded exposure with defined-risk downside protection around US drug-pricing policy milestones, since a reduction in compound alternatives could strengthen the political case for mandated price concessions.